U.S., Feb. 19 -- ClinicalTrials.gov registry received information related to the study (NCT06832189) titled 'EVR and EPO for Liver Transplant Tolerance' on Feb. 12.
Brief Summary: This is an open label, single-arm, multicenter phase 1b study of stable adult liver transplant recipients on a tacrolimus (TAC)-based immunosuppression (IS) regimen who will transition from TAC to Everolimus (EVR), receive five doses of EPO and concurrently initiate phased withdrawal from EVR.
The primary objective is to test the safety of administering Everolimus (EVR) and epoetin alfa (EPO) to induce operational tolerance in stable adult liver transplant recipients
Study Start Date: June 01, 2025
Study Type: INTERVENTIONAL
Condition:
Liver Transplant
Inte...